Treatment of Mouse Limb Ischemia with an Integrative Hypoxia-Responsive Vector Expressing the Vascular Endothelial Growth Factor Gene by Yasumura, Eduardo Gallatti et al.
Treatment of Mouse Limb Ischemia with an Integrative
Hypoxia-Responsive Vector Expressing the Vascular
Endothelial Growth Factor Gene
Eduardo Gallatti Yasumura, Roberta Sessa Stilhano, Vı´vian Yochiko Samoto, Priscila Keiko Matsumoto,
Leonardo Pinto de Carvalho, Valderez Bastos Valero Lapchik, Sang Won Han*
Research Center for Gene Therapy, Department of Biophysics, Universidade Federal de Sa˜o Paulo, Sa˜o Paulo, Sa˜o Paulo, Brazil
Abstract
Constitutive vascular endothelial growth factor (VEGF) gene expression systems have been extensively used to treat
peripheral arterial diseases, but most of the results have not been satisfactory. In this study, we designed a plasmid vector
with a hypoxia-responsive element sequence incorporated into it with the phiC31 integrative system (pVHAVI) to allow
long-term VEGF gene expression and to be activated under hypoxia. Repeated activations of VEGF gene expression under
hypoxia were confirmed in HEK293 and C2C12 cells transfected with pVHAVI. In limb ischemic mice, the local administration
of pVHAVI promoted gastrocnemius mass and force recovery and ameliorated limb necrosis much better than the group
treated with hypoxia-insensitive vector, even this last group had produced more VEGF in muscle. Histological analyses
carried out after four weeks of gene therapy showed increased capillary density and matured vessels, and reduced number
of necrotic cells and fibrosis in pVHAVI treated group. By our study, we demonstrate that the presence of high
concentration of VEGF in ischemic tissue is not beneficial or is less beneficial than maintaining a lower but sufficient and
long-term concentration of VEGF locally.
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Introduction
Peripheral arterial disease (PAD) is characterized by arterial
narrowing that reduces oxygen supply to the extremities resulting
in severe pain, non-healing ulcers and possible loss of the affected
limb. The incidence of PAD is high at about 1000 affected per
million individuals, and this incidence increases in individuals over
70 years of age and in diabetics [1]. According to the Transatlantic
Inter-Society Consensus, approximately 25% of patients with
advanced PAD will suffer amputation because conventional
medical and revascularization treatments are not feasible. The
prognosis for these patients is bad; after one year, about 25% of
them will die, and 20% will still have PAD [1]. Therefore, it is
necessary to continue the search for new therapies.
The main cause of PAD is atherosclerosis, which leads to
narrowing and malfunctioning of arteries, i.e., ischemia. Conse-
quently, current therapies promote new vessel formation by
administering growth factors, which can be provided in protein or
gene form or even as cells that produce these factors naturally or
after genetic modification [2–4]. Among several growth factors
used for angiogenic therapy, vascular endothelial growth factor
(VEGF) has been the most extensively studied because it is a
potent mitogenic factor that also has anti-apoptotic and vessel
dilation activities [5,6]. This factor acts primarily on endothelial
cells through the VEGFR1 and VEGFR2 receptors, but it also
promotes chemotaxis of smooth muscle cells, monocytes and bone
marrow progenitor cells [6–8]. In animal studies, VEGF has been
shown to improve perfusion and to increase capillary density in
ischemic limbs [9–15]. Many of these studies have advanced to
clinical trials, but most of the results have not been satisfactory.
To date, all clinical trials on limb ischemia treatment have used
plasmid or adenoviral vectors designed to express transiently and
locally [2–4], and muscle has been the favorite target tissue.
Transgene expression is transient because the genes are not
integrated into the host genome. In clinical trials, these vectors are
injected directly into the muscle at high enough doses to express
high levels of angiogenic factors due to the characteristics of these
vectors. As the angiogenic factor concentration required in loco to
induce a therapeutically beneficial amount of angiogenesis is
variable depending on the degree of ischemia, angiogenic gene
therapy in some tissues can induce hemangioma due to the
exaggerated production of growth factors [16,17], and in other
tissues, it cannot ameliorate ischemia due to insufficient produc-
tion of the angiogenic factor. Thus, the ideal vector system should
have a mechanism to allow for the long-term production of
angiogenic factors according to the local degree of ischemia.
To obtain a vector that is responsive to ischemia and is capable of
long-term VEGF expression, we designed an integrative plasmid
vector based on the WC31 integrase system that contains an HRE
(hypoxia-responsive element) sequence. The HRE consensus se-
quence, isolated from the 39 end of the erythropoietin (Epo) gene, is
present in many genes involved in erythropoiesis, angiogenesis and
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glycolysis [18] that are activated during hypoxia. Cells and tissues
exposed to hypoxia trigger an adaptive response driven by hypoxia
induced factor 1 (HIF-1), which binds to the HRE sequence located
in the enhancer regions of these genes. It has been demonstrated that
vectors constructed with an HRE sequence provide enhanced
transgene expression under hypoxic conditions through HIF-1
binding to the HRE [18,19]. In addition, to allow for integration of
the vector, the attB sequence from phage WC31 was included. The
integrase from WC31 recognizes plasmids with the attB sequence and
inserts them into genomic regions containing pseudo-attP sequences
[20], which are present in mammalian genomes. Because the
integration process is unidirectional, once the plasmid is inserted into
the genome, it is maintained stably [21]. In our study, we found that
limb ischemic mice treated with our integrative vector that is
responsive to variations in oxygen concentration had a better
therapeutic response than mice treated with other delivery vectors.
Materials and Methods
Vector construction
The commercially available pVAX vector (Invitrogen, Carlsbad,
EUA) was cut with HincII enzyme, and a cassette containing 9
copies of the HRE sequence (CCGGGTAGCTGGCG-
TACGTGCTGCAG) from the AAV-H9-lacZ vector (kindly
provided by Dr Hua Su, The Cardiovascular Research Institute,
University of California, USA [22], which was obtained by digesting
with EcoRI and BglII and treating with Klenow polymerase, was
ligated to make pVAX-HRE. This vector was digested with NruI
and was ligated with the attB sequence from the pTA-attB vector
(kindly provided by Dr Michele P. Calos, Genetics department of
Stanford University, USA [20]), which was previously digested with
BamHI and EcoRV and treated with Klenow polymerase, to make
pVAX-HRE-attB. Finally, to insert the human VEGF165 sequence
into pVAX-HRE-attB, both it and the uP-VEGF vector [23], which
expresses human VEGF165, were digested with HindIII and ApaI
and ligated together to make pVAX-HRE-attB-VEGF. The
integrase expression vector uP-INT was constructed by inserting
theWC31 integrase gene into the uP vector. The p-INT vector has a
construction similar to uP-INT, but it does not have a CMV
promoter; therefore, it does not express integrase (Fig. 1).
Cell culture under normoxia and hypoxia
The human embryonic kidney cell line HEK293T [24] was
maintained in DMEM supplemented with 10% fetal bovine serum
(DMEM+). For transfection, in a 6-well plate 16105 HEK 293
cells were seeded. Twenty-four hours later, 2.5 mg of the donor
plasmid containing hVEGF165 and 2.5 mg of pVAX or p-INT or
uP-INT plasmids were mixed for transfection by the calcium-
phosphate co-precipitation method. After 24 h, the medium was
replaced with a fresh one, and at the indicated time, the
supernatant was collected to determine VEGF levels by ELISA.
To establish hypoxic condition in vitro, the cells were cultured
with DMEM+ containing 100 mM cobalt chloride [25]. To test the
toxicity of the cobalt, HEK293 cells were cultured with 0, 200 or
400 mM cobalt chloride, and cell viability was assessed using the
Trypan blue method.
The mouse myoblast cell line (C2C12) was also maintained in
DMEM+, but for transfection the Amaxa NHDF Nucleofector kit
and Nucleofector Amaxa (Lonza, Basel, Switzerland) were used
following the provided protocol.
Ischemic hind limb model and muscular transfection
All procedures involving animals were approved by the
Research Ethics Committee of the Federal University of Sa˜o
Paulo, Brazil (Approval number: CEP 0729/08). Initially, 10–12
week-old Balb/c male mice were anesthetized with an intraper-
itoneal injection of ketamine (40 mg/kg) and xylazine (20 mg/kg).
Hind limb ischemia was induced surgically as previously described
[26,27]. Briefly, the femoral artery was excised from its origin at
the external iliac artery branch to its bifurcation into the
saphenous and popliteal arteries without damaging the femoralis
vein or nerves. Branches including the circumflex artery were also
obstructed completely to avoid retrograde flow. Gene therapy was
performed by injecting 50 mg of each vector in 100 ml of
phosphate-buffered saline (PBS) into the middle of the quadriceps
muscle soon after ischemic surgery. After plasmid injection, 3
electric pulses of 80 V/cm and 20 ms in duration were applied
using needle electrodes (Electroporator T820; BTX Genetronics,
San Diego, USA). After gene therapy, the animals were kept under
analgesia with daily peritoneal injections of 5 mg/kg carprofen. In
our study, the following groups were included with 7–10 animals
per group: normal, ischemic and ischemic treated with vector.
Visual assessment of necrosis
Limb ischemia was visually evaluated 30 days after treatment.
The following four grades were used to measure the degree of limb
necrosis: grade 0, absence of necrosis; grade 1, necrosis limited to
the toes; grade 2, necrosis extending to the dorsum pedis; grade 3,
necrosis extending to the crus [26].
Muscle force determination
Isometric gastrocnemius muscle contraction was performed 30
days after treatment based on a previous study [28]. The animals
Figure 1. Schematic vector diagrams. (A) pVAX-HRE-attB-hVEGF165; (B) pVAX-attB-hVEGF165; (C) pVAX-hVEGF165; (D) uP-INT; (E) p-INT. pUC ori:
replication origin. Pcmv: human cytomegalovirus promoter. BGHpA: polyadenylation signal of the bovine growth hormone. Kanamycin: kanamycin
resistance gene.
doi:10.1371/journal.pone.0033944.g001
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were anesthetized and maintained at 37uC on a temperature-
controlled plate. The leg and knee were fixed on the plate with the
gastrocnemius muscle exposed. The Achilles tendon was cut and
attached to a wire connected to a force transducer (MLT 1030/D
- ADInstruments, Bella Vista NSW, Australia). The lateral
gastrocnemius and soleus muscles were removed; the vascular
and nerve systems were kept intact. Medial gastrocnemius muscles
were left free from the surrounding tissue to minimize effects from
the contraction of other muscles. The sciatic nerve was isolated
and placed in contact with a bipolar silver electrode for electro-
stimulation. One stimulus of 5 volts at a frequency of 60 Hz was
applied for 10 ms with a 1 minute interval between stimulations.
The isometric contractions were measured as the highest force
stretching the wire. All collected data were recorded and analyzed
using the PowerLab 8/30 system and LabChart Pro software
(ADInstruments, Bella Vista NSW, Australia). After force
determination, the animals were subjected to euthanasia, and
their medial gastrocnemius muscles were then removed for mass
measurement and histological analysis.
Determination of hVEGF165 by ELISA
Supernatant from cultured cells was collected periodically to
determine the concentration of hVEGF165 using a DuoSet ELISA
kit (R&D Systems Inc., Minneapolis, USA) following the
manufacturer’s instructions. To determine hVEGF165 levels in
muscle, the quadriceps muscle was removed after muscle force
measurement. The middle part of the gastrocnemius muscle was
mechanically homogenized using lysis buffer (25 mM Tris-HCl,
pH 7.4, 50 mM NaCl, 0.5% Na-deoxycholate, 2% NP-40, 0.2%
sodium dodecyl sulfate, 1 mM phenylmethylsulphonyl fluoride).
The homogenized tissue was centrifuged at 45006g for 10 min at
4uC, and the supernatant was recovered. Total protein and
hVEGF165 concentrations were determined using the Bio-Rad
Protein Assay (BioRad, California, USA) and a DuoSet ELISA
Kit, respectively.
Gene expression analysis by quantitative reverse
transcription polymerase chain reaction (qRT-PCR)
Total RNA from C2C12 or HEK293 cells was extracted with
Trizol reagent (Invitrogen, Carlsbad, CA, USA) and treated with
DNAse I (Invitrogen). cDNA was synthetized using High Capacity
cDNA Reverse Transcription kit (Invitrogen) and qRT-PCR was
conducted using QuantiFast SYBR Green RT-PCR Kit (Qiagen,
Hilden, Germany) in the Rotor Gene-Q (Qiagen). The following
primers were used to quantify mouse HIF1- a (m HIF1- a), human
HIF1- a (h HIF1- a) and human VEGF (hVEGF): mHIF1-a_F
(gca gca gga att gga acat t), mHIF1-a_R (gcat gct aaa tcg gag
ggta), hHIF1-a_F (caa gaa cct act gct aat gc), hHIF1-a_R (tta tgt
atg tgg gta gga gat g), hVEGF_F (ttc tgc tgt ctt ggg tgc att gg),
hVEGF_R (gaa gat gtc cac cag ggt ctc g). Relative gene expression
was calculated by 22DCT. The changes in mRNA expression were
expressed as fold-changes relative to control, which was the RNA
from C2C12 or HEK293 cells without cobalt and transfection. As
normalizer of qRT-PCR, the ribosomal gene hRPS29 was used
with primers hRPS29_F (gag cca ccc gcg aaa at) and hRPS29_R
(ccg tgc cgg ttt gaa cag) for HEK 293 and the murine b-actin gene
with primers mb-actin_F (gct cct cct gac cgc aag) and mb-actin_R
(cat ctg ctg gaa ggt gga ca) for C2C12. Each reaction was carried
out in duplicate and all experiments were carried more than three
times. Values were expressed in the mean 6 standard error of the
mean. One way ANOVA with Bonferronis’s multiple comparison
was used to statistical analysis.
Vector integration analysis by PCR
Genomic DNA was extracted from quadriceps muscles or from
transfected HEK293 cells using the QIAMP DNA Mini Kit
(QIAGEN Inc., Valencia, USA). To check for vector integration
into the host genome, a PCR reaction was carried out using a pair
of primers, CMV reverse 59-TCATTATTGACGTCAA
TGGGC-39 and attB sense 59-CTCCACCTCACCCATCT-39,
at a final concentration of 0.5 mM. The PCR reaction was
performed by programming a thermocycler to 94uC for 1 min and
35 cycles of 94uC/1 min, 52uC/1.5 min and 72uC/1 min. After
the final cycle, the reaction continued for 7 min at 72uC, and the
tubes were then maintained at 4uC. As an internal control for the
PCR, the glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
housekeeping gene was used with GAPDH sense (59-ACCA-
CAGTCCATGCCATCAC-39) and GAPDH antisense (59-
TCCACCACCCTGTTGCTGTA-39) primers. The PCR prod-
ucts were analyzed by 1% agarose gel electrophoresis with
ethidium bromide staining.
Histological analysis
Muscle samples were fixed in 10% formaldehyde, dehydrated
and embedded in paraffin. Four micrometer sections were
obtained and stained with hematoxylin-eosin (HE) and picrosirius.
The extent of necrosis, muscle regeneration and fibrosis were
analyzed from 20 fields and quantified using Image Pro Plus
software (Media Cybernetics, Inc., Bethesda, USA). Other sections
were collected in poly L-lysine coated slides and submitted for
immunohistochemistry with biotinylated Griffonia (bandeiraea)
simplicifolia lectin I (1:100) (Vector Laboratories, Peterborough,
UK) or anti-alpha smooth muscle actin antibody (1:50) (Vector
Laboratories, Peterborough, UK) followed by incubation with
streptavidin conjugated peroxidase (Sigma-Aldrich, Saint Louis,
USA) and detection with diaminobenzidine chromogen. Vessel
and capillary densities were quantified from 20 random fields per
slide. The results were expressed as the average number per square
millimeter.
Statistical analysis
The results were expressed as mean 6 standard error of the
mean. Analysis of variance (ANOVA) was performed using a
Bonferroni correction for multiple comparisons or a Mann-
Whitney test for a comparison of two groups. Visual assessment of
necrosis was analyzed by the one way ANOVA with Tukey’s
multiple comparison tests. Only P,0.05 was considered signifi-
cant.
Results
In vitro evaluation of VEGF gene expression
To assess the functionality of the constructed vectors (Fig. 1),
HEK293T cells were transfected with these vectors, and VEGF
gene expression was monitored for more than 90 days (Fig. 2). The
calcium co-precipitation method was used to transfect HEK293T
cells because this method achieves more than 90% transfection
efficiency in this cell line (data not shown). To induce hypoxia,
CoCl2 was added to the medium at a final concentration of
100 mM, which is a concentration commonly used to mimic
hypoxia [24]. HEK293T cells incubated with 100 mM CoCl2 for
nine days retained about 90% cell viability (data not shown).
Under normoxia conditions, all groups showed a peak of VEGF
gene expression at 48 hours post-transfection, which is a well-
known transient gene expression pattern, but by the 14th day,
VEGF expression in all groups had returned to basal levels (Fig. 2).
Cells transfected with the integrative vectors pVAVI and pVHAVI
Integrative Hypoxia-Responsive Vector for Ischemia
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Figure 2. Assessment of VEGF expression vectors. (A) hVEGF165 production under hypoxia and normoxia in HEK293 cells. On days 28, 47 and 74,
CoCl2 was added to a final concentration of 100 mM, and the medium was replaced every 3 days with fresh medium containing CoCl2 for 9 days (gray
bars). -&- no transfection; -m- pVV; -.- pVAV; -e- pVAVI; -N- pVHAV; -%- pVHAVI. * p,0.001, pVHAVI in comparison to all groups. (B) Genomic DNA PCR
after 4 weeks of transfection. 1: no transfection; 2: pVV; 3: pVAV; 4: pVAVI; 5: pVHAV; 6: pVHAVI; 7: pVAX-attB-hVEGF165 (432 bp); 8: pVAX-HRE-attB-
hVEGF165 (725 bp). The 200 bp band is from GAPDH. * 100 bp ladder. pVV: pVAX-hVEGF165 + pVAX; pVAV: pVAX-attB-hVEGF165 + p-INT; pVAVI: pVAX-
attB-hVEGF165 + uP-INT; pVHAV: pVAX-HRE-attB-hVEGF165 + p-INT pVHAVI: pVAX-HRE-attB-hVEGF165 + uP-INT (C) HIF1a and (D) hVEGF165 expression in
HEK293 cells. On day 15 the HEK293 cells from the experiment (A) were collected for analysis by qRT-PCR. CTL: control; Co: CoCl2 ; * p,0.05. (E) hVEGF165
production under hypoxia and normoxia in C2C12 cells. On day 18 CoCl2 was added to a final concentration of 100 mM and 3 days later the mediumwas
collected for VEGF quantification by ELISA. -&- no transfection; -N- pVHAV; -%- pVHAVI. * p,0.05. (F) HIF1a and (G) hVEGF165 expression in C2C12 cells.
On day 15 the C2C12 cells from the experiment (C) were collected for analysis by qRT-PCR. CTL: control; Co: CoCl2 ; * p,0.05 of pVHAVI_Co group versus
all other groups.
doi:10.1371/journal.pone.0033944.g002
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still maintained about 500 pg/ml VEGF expression, whereas
those transfected with non-integrative vectors expressed about half
of this value. On the 28th day, CoCl2 was added to the culture
medium and maintained for 9 days. Three days after CoCl2
addition, VEGF production was found to be enhanced only in the
pVHAVI transfected cells; it reached about 900 pg/ml but
returned to basal levels later. The pVAVI group did not show
any increase in VEGF levels during the first 3 days, and these
levels diminished even more in subsequent days. Upon removing
CoCl2, VEGF gene expression levels returned to their initial
status.
Activation of VEGF gene expression by CoCl2 was repeated on
the 47th and 74th days and resulted in a very similar pattern of
gene expression. After the third stimulation, the experiment was
stopped because most of the cells became unviable. Long-term cell
culturing with CoCl2 seems to affect cell viability. These results
clearly demonstrate that the vectors functioned correctly, partic-
ularly the pVHAVI system, which is the only system that is
expected to be hypoxia-responsive.
To verify genomic integration of the pVHAVI and pVAVI
vectors, genomic DNA was extracted 30 days after transfection,
and a known region of the vectors was amplified by PCR. Fig. 2B
shows the amplification of 735 bp and 432 bp products, which
correspond to the pVAX-HRE-attB-hVEGF165 and pVAX-attB-
hVEGF165 vectors, respectively. DNA from the other vectors was
not amplified by PCR.
To demonstrate the activation of HIF1a by CoCl2, the
expression of HIF1a and hVEGF genes was evaluated by qRT-
PCR at the 15th day. Irrespective of the presence or not of vectors,
the presence of CoCl2 in the medium elevated HIF1a gene
expression 7 to 11 folds in relation to cells without CoCl2 (Fig. 2C);
however, only those cells transfected with pVHAVI had elevated
VEGF gene expression in the presence of CoCl2 (Fig. 2D),
indicating the correct functioning of the pVHAVI system.
To strengthen these findings, we tested pVHAVI system in the
murine myoblast cell line C2C12, which is the main cell type
present in skeletal muscles. To transfect this cell line we chose
nucleofection method, because we had very low level of
transfection with calcium phosphate co-precipitation method
(not shown). Even using nucleofection the VEGF gene expression
levels were lower than HEK293 cells, but the profile of gene
expression over 21 days was very similar (Fig. 2E). At the 3rd day
after transfection, VEGF gene expression reached about
7,000 pg/ml by both pVHAVI and pVHAV systems, but in a
week it dropped to basal level and, at 14th day, there was no
significant difference of gene expression between these two
systems.
CoCl2 was added to cell culture media at the 18
th day, but only
those cells transfected with pVHAVI had increased hVEGF gene
expression, meanwhile the cells transfected with pVHAV or non-
transfected ones did not have any significant alterations. Activation
of HIF1a by CoCl2 was also seen in C2C12 cells (Fig. 2F), which
was about 7 and 4 folds higher than control group by pVHAVI
and pVHAV systems, respectively, but only pVHAVI transfected
cells had increased hVEGF gene expression (Fig. 2G).
Visual, functional and molecular analyses of muscles after
gene therapy
Visual assessment is an easy method to carry out and provides
consistent and relevant information. To make this type of
assessment quantitative, the degree of necrosis was scored as
described in the ‘‘Materials and Methods’’ section. All animals in
the ischemic group without gene therapy presented grade 1 or 2
necrosis. Two animals from the pVV group presented no necrosis,
demonstrating the therapeutic effect of the treatment, but the rest
of group still showed some degree of necrosis. The pVAVI-treated
animals had a better outcome than the pVV group because about
half of them had no necrosis. However, the best result was
obtained with pVHAVI treatment, which resulted in no visual
necrosis in any animals in the group (Fig. 3).
To assess muscle functioning, the gastrocnemius muscle force
was determined after 4 weeks of gene therapy. Ischemic limbs
showed a drastically reduced force from 1.04 N to 0.12 N, but
pVHAVI-treated animals exhibited a force of about 0.46 N, which
is equivalent to a 400% improvement. pVV- and pVAVI-treated
animals reached an intermediate score of 0.3 N (Fig. 4A). The
weight of the gastrocnemius muscle varied among the groups in a
pattern similar to that of the muscle force variation. In the
pVHAVI-treated animals, this weight was about 50% that of the
non-ischemic animals, whereas in the other groups, it was only
about 36% (Fig. 4B). It is important to note that the untreated
ischemic animals had a similar muscle weight compared to those
treated with pVV or pVAVI, but in terms of muscle force, the
untreated ischemic group had a much lower value. Muscle force
depends on the number and volume of correctly functioning
muscle fibers, whereas muscle mass encompasses the mass of all
tissues including non-contractile fibrotic tissues, the amount of
which varies with disease evolution. Therefore, a minor variation
between muscle mass and force after 4 weeks of ischemia is
expected.
The pVAVI and pVHAVI vectors are integrative systems, and
consequently, gene delivery using these vectors is expected to
result in long-term gene expression. To validate the correct
functioning of these vectors, VEGF gene expression was evaluated
in both serum and muscle tissue. In serum, VEGF was not
detected at any time in any group. Muscle extracts obtained after
30 days from the pVHAVI and pVAVI groups had about 3.3 and
4.2 pg/mg of VEGF, respectively, and the ischemic and pVV-
treated groups had less than 1.5 pg/mg (Fig. 5A). As 1.5 pg/mg is
at the limit of VEGF detection by ELISA, we considered this to be
a null value.
To check for vector integration in host cells, PCR was
performed using genomic DNA obtained from muscles as a
Figure 3. Visual assessment of ischemic limbs after gene
therapy. Four weeks after gene therapy, limbs were evaluated
according to the following necrosis scale: grade 0: absence of necrosis;
grade I: necrosis limited to the toes; grade II: necrosis extending to the
dorsum pedis, grade III: necrosis extending to the crus. * P,0.05;
** P,0.005.
doi:10.1371/journal.pone.0033944.g003
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template. DNA bands of 735 bp and 432 bp were detected in the
pVHAVI and pVAVI groups, respectively, and these correspond
to the pVAX-HRE-attB-hVEGF165 and pVAX-attB-hVEGF165
vectors, respectively (Fig. 5B). Other groups showed no amplifi-
cation, indicating that no vector integration had occurred after 30
days.
Histological analyses
Gastrocnemius muscles were stained with HE, and the numbers
of necrotic, normal and regenerative cells were quantified (Fig. 6A
and 6B). The ischemic group showed about 15 cells/mm2 of
necrotic cells, and this was reduced to 5 cells/mm2 in the
pVHAVI-treated group. Moreover, the normal cell count
increased from 5 cells/mm2 in the untreated ischemic group to
almost 20 cells/mm2 in the pVHAVI-treated group. The groups
treated with the other vectors showed intermediate values. In
terms of regenerative cell count, the pVHAVI group (12 cells/
mm2) had a smaller count than the pVAVI group (18 cells/mm2)
but a much higher count than the ischemic group (4 cells/mm2).
A similar order of fibrotic area was seen after staining with
Picrossirus (Fig. 6C): ischemic.pVV.pVAVI.pVHAVI.nor-
mal. These findings corroborate the previously obtained results
demonstrating that the therapeutic effect of pVHAVI is better
than that of either the non-integrative pVV system or the
integrative and constitutive pVAVI system.
To evaluate angiogenic activity promoted by VEGF, vessels
were stained with lectin Griffonia, which recognizes endothelial
vessels and macrophages. This staining system was chosen over
staining with an anti-CD31 antibody to allow both vessels and
infiltrated macrophages to be visualized in the same section.
Macrophages and endothelial cells can be differentiated easily by
optical microscopy using high magnification. In addition, the anti-
alpha-actin antibody was used to localize mature and larger
vessels. The number of vessels stained with the two systems was
similar (Fig. 6D and 6E). The pVHAVI-treated group had the
highest number of vessels followed by the pVAVI and the pVV
groups. Even though the difference between the pVHAVI and
pVAVI groups was not statistically significant, the pVHAVI
treatment tended to be superior.
Discussion
Since the first clinical trial of gene therapy for the treatment of
ischemic limbs (which used a plasmid vector expressing the VEGF
gene) by Jeffrey Isner in 1996 [29], more than 150 gene therapy
trials have been initiated, and about half of them are still opened
(http://www.wiley.co.uk/genetherapy/clinical/). The VEGF gene
has been widely used in preclinical and clinical assays to treat
ischemic diseases because it is a pleiotropic factor involved in
many cellular activities, most of which are closely related to
angiogenesis. In most of the animal studies, vectors expressing
VEGF have been injected directly into the ischemic tissue, and this
was found to improve blood flux and transiently augment vessel
density [2]. However, we and other groups have demonstrated
that long periods of high expression of this gene in ischemic tissue
can lead to deleterious effects, such as a decrease in capillary
density, the loss of muscle mass and force and the augmentation of
limb necrosis [27,30,31]. It is likely that the high concentration of
VEGF provided by the ischemic tissues together with the
transfected cells promotes fast endothelial cell proliferation and
vessel formation, which are not followed by adequate vessel
maturation. These premature vessels in muscles can be easily
disassembled by muscular movements, potentially leading to
Figure 4. Determination of the mass and force of the gastrocnemius muscle. Muscle force (A) and mass (B) were measured 4 weeks after
gene therapy. For each group, seven mice were used. The sham-operated and non-ischemic groups showed no difference in their results and are
denoted here as normal. (A) * P,0.05; ** P,0.005. (B) * P,0.05, pVHAVI in comparison to each group.
doi:10.1371/journal.pone.0033944.g004
Figure 5. Assessment of VEGF expression vectors after gene
therapy. (A) Concentration of hVEGF165 in the quadriceps muscle: -x-
Ischemic; -&- Normal; -m- pVV; -N- pVHAVI; - e - pVAVI. (B) Genomic
DNA PCR after four weeks of gene therapy. 1: normal; 2: pVV; 3: pVAVI
(432 bp); 4: pVHAVI (725 bp). The 200 bp band is from GAPDH.
* 100 bp ladder.
doi:10.1371/journal.pone.0033944.g005
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edema and cell death. Using VEGF together with either the stem
cell mobilizing factor G-CSF (granulocyte colony stimulating
factor) or the arteriogenic and vasculogenic factor GM-CSF
(granulocyte macrophage-colony stimulating factor) to treat mouse
ischemic limbs has resulted in much better outcomes than
treatment with VEGF alone [26,27]. Our interpretation of these
results is that, to make a stable and functional vessel, it is necessary
to recruit more growth factors and cells in an adequate time frame
and at adequate concentrations, as happens physiologically.
In angiogenic gene therapy assays, plasmid and adenoviral
vectors are primarily used because they provide efficient gene
transfer to muscles in vivo and express transgenes transiently. Most
(if not all) of these vectors are designed to express transgenes highly
and continuously using strong constitutive promoters, with the
expectation that the secreted angiogenic factors will be spread
around the whole ischemic area. However, most angiogenic
factors like VEGF contain a heparin-binding domain in their
structure [32–34], which causes these factors to be retained
around the production area. Consequently, an area with cells
transfected with VEGF produces this factor continuously irre-
spective of the local production due to ischemia, making the local
concentration higher than necessary after a certain period of time.
Such a condition usually leads to the formation of unstable,
immature and hypofunctional vessels [16,35]. The best way of
expressing VEGF for therapy is ideally by using vectors that
respond to the requirements of the local tissue, i.e., vectors that are
regulated by the local degree of ischemia, as normal cells are.
Physiological VEGF gene expression is modulated by the local
oxygen concentration. In ischemic tissue, the oxygen supply is
limited, and oxygen distribution occurs mostly by passive diffusion
from arteries to tissues [36]. This is one of the reasons that limbs
distant from the obstructed artery are more affected than proximal
limbs. Therefore, it is expected that the degree of ischemia, or the
degree of oxygenation, will be variable in different parts of
ischemic tissue. In this manner, VEGF production should
correlate with either the degree of ischemia or the oxygen
concentration. In humans, to overcome the ischemic condition,
the ischemic tissues naturally express angiogenic factors based on
the local oxygen concentration, such as VEGF, which is monitored
by HIF-1 [37]. HIF-1a translocates to the nucleus during hypoxia,
where it associates with HIF-1b to make a dimer, which in turn
activates genes containing HRE (hypoxia responsive element)
sequences. Genes involved in survival under hypoxic conditions,
such as those that regulate angiogenesis, vessel dilation, erythro-
poiesis and glycolysis, are regulated by the binding of HIF to the
HRE [19,37].
To make a VEGF-expressing vector responsive to hypoxia, we
used nine repeats of the HRE sequence, which is responsive to
HIF. A vector with nine repeats was used because it functioned
better than vectors with fewer repeats [38]. In addition, with the
goal of making an integrative vector capable of providing long-
term VEGF expression, the phiC31 integrase system was used.
This system allows integration of the vector in one direction, i.e.,
once the vector is integrated into the host genome it cannot be
removed enzymatically [20,21]. Using this system, our expectation
was that one treatment of an ischemic limb with the vector
(pVHAVI) would be sufficient for a long period, and VEGF gene
expression would be regulated by the vector itself.
To demonstrate that the pVHAVI system was functioning
correctly, these vectors were tested in vitro using HEK293T cells
and myoblast cell line C2C12 and in vivo using a mouse ischemic
limb model. In our in vitro study, HEK293T cells were transfected
with several vectors (Fig. 1), and VEGF gene expression was
followed for more than 90 days. The pVHAVI system was the only
one that responded to hypoxia, which was induced by CoCl2 to
stabilize HIF1a from degradation. It is important to note that
hypoxia was induced at three different times and the cells modified
with pVHAVI responded precisely to the hypoxic signal each
time. A very similar result was also seen in C2C12 cell line. These
results demonstrate clearly that VEGF expression can be activated
at any moment by hypoxia, as we predicted.
Correct functioning of the pVHAVI system, as indicated by the
induction of VEGF gene expression by hypoxia, was observed for
a month. In this study, we opted to use the limb ischemia model
rather than administration of CoCl2 because the first model is
much more similar to human ischemic disease, and it is a well-
established animal model [26,27,39]. Additionally, we have not
found a method for using CoCl2 to induce ischemia in vivo or any
other method that can induce limb ischemia repeatedly without
significantly affecting the animal’s physiology. As a result, we could
not induce hypoxia repeatedly in animals to evaluate the
functioning of the pVHAVI system over a long period as we
could for the in vitro model. Consequently, we chose to evaluate
the system indirectly after gene therapy by examining therapeutic
parameters such as alterations in muscle mass, force and histology
and by visually assessing muscle necrosis. For in vivo gene
transference, electroporation was used because in our previous
studies, we demonstrated that this method is reproducible and
results in high levels of transfection [26,27].
The first important step in our in vivo study was to demonstrate
that the pVHAVI and pVAVI systems were integrated into muscle
cells by phiC31 integrase after one month, and this was proven by
PCR (Fig. 5B). It is also very important to note that both systems
produced VEGF at a similar level (Fig. 5A), but the physiological
response was quite different between them, as follows: 1) most of
the animals treated with pVHAVI showed no necrosis, whereas
half of those treated with pVAVI had some degree of necrosis
(Fig. 3); 2) muscle weight and force were higher in animals treated
with the pVHAVI system (Fig. 4A and 4B) and 3) the degree of
angiogenesis and fibrosis was better with the pVHAVI system than
the pVAVI system (Fig. 6).
Even though the VEGF concentration in muscles was similar in
both systems, it is important to note that this concentration was
determined from the whole muscle only once, at the 4th week, due
to limitations of the method. Therefore, whether any variation in
VEGF gene expression occurred in different parts of the muscle
after transfection with either vector system during the 4 weeks is
unknown. However, it is reasonable to assume that the pVHAVI
system, which mainly expresses VEGF during hypoxia, acted
differently than the pVAVI system, which expresses VEGF
constitutively. We have no direct evidence to support this
assumption, but the in vitro data and the improvement of animals
Figure 6. Morphometric analysis of limb muscles. The gastrocnemius muscle was collected from mice after four weeks of gene therapy. Tissue
samples were stained with HE (A) and used to quantify necrotic, regenerative and normal areas (B). The sham-operated and non-ischemic groups
showed no difference in their results and are denoted here as normal. Fibrotic area, capillary density and mature vessel density were determined after
staining with Picrosirius (C), Griffonia (D) and alpha-actin antibody (E), respectively. Bar = 50 mm. * p,0.05. m, Infiltrated mononuclear cells; X,
adipocytes; R, capillary; In the figure B, pVHAVI was different statistically in comparison to all groups.
doi:10.1371/journal.pone.0033944.g006
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treated with the pVHAVI system allow us to make this
interpretation.
In this study, the viral CMV promoter was used to construct
pVHAVI, which promoted hVEGF expression for three months in
vitro and one month in vivo, at least. However, it is a well-known
phenomenon that viral promoters, used to express mammalian
genes, are frequently silenced during long-term studies. The use of
muscle specific promoters like MCK (muscle creatine kinase) in
construction of pVHAVI can bring better benefit to PAD patients
in long-term treatment.
In conclusion, we demonstrated that a plasmid vector with an
HRE sequence incorporated into it provides hypoxia-inducible
VEGF expression. This vector, produced with the phiC31
integrative system, allowed for long-term VEGF gene expression,
which was only activated under hypoxic conditions. For the
treatment of mouse limb ischemia, the hypoxia-sensitive vector
pVHAVI ameliorated the symptoms much better than the
hypoxia-insensitive vector pVAVI. This last result corroborates
the idea that the presence of high concentrations of VEGF in
ischemic tissue is not beneficial or is less beneficial than
maintaining a lower but sufficient and long-term concentration
of VEGF locally.
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